Although many cancer-related studies on MGL interactions may confirm their immunosuppressive properties, there are several recent reports indicating a correlation between low MGL expression and worse outcomes of cancer patients, including hepatocellular carcinoma, melanoma, lung adenocarcinoma, breast cancer, and head and neck squamous cell carcinoma [113,114,115,116,117,118]. The gene discussed is CLEC10A; the disease is breast cancer.